Silvana Acquafredda
Overview
Explore the profile of Silvana Acquafredda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rizzo A, Cusmai A, Massafra R, Bove S, Comes M, Fanizzi A, et al.
Cells
. 2022 Jun;
11(12).
PMID: 35740985
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs...
2.
Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, et al.
Future Oncol
. 2022 Apr;
18(18):2301-2309.
PMID: 35378995
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses of early breast cancer. Novel systemic treatment options have recently been assessed as part of the neoadjuvant approach,...
3.
Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326555
(1) Background: In recent years, immunotherapy has revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), representing a therapeutic breakthrough in this field. Antacid agents such as proton pump...
4.
Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, et al.
Expert Rev Gastroenterol Hepatol
. 2022 Feb;
16(3):273-278.
PMID: 35220866
Background: The 2021 has seen the publication of two practice-changing trials on second-line fluoropyrimidine-based doublet chemotherapy for advanced biliary tract cancer (BTC) patients. Herein, we conducted a meta-analysis aimed at...
5.
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
Rizzo A, Ricci A, Cusmai A, Acquafredda S, De Palma G, Brandi G, et al.
Curr Oncol
. 2022 Feb;
29(2):551-564.
PMID: 35200550
Recent years have seen some breakthroughs in the therapeutic landscape of advanced biliary tract cancer (BTC). Firstly, a better understanding of the molecular background of BTC has led to important...
6.
Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G
Expert Opin Investig Drugs
. 2022 Feb;
31(6):495-498.
PMID: 35171746
No abstract available.
7.
Notarnicola M, Felli E, Roselli S, Altomare D, De Fazio M, DeAngelis N, et al.
Surg Endosc
. 2019 May;
33(9):2763-2773.
PMID: 31139986
Laparoscopic liver resection (LLR) is becoming standard practice, replacing the open approach in terms of safety and feasibility. However, few data are available for the elderly. The objective of this...
8.
Acquafredda S, Tafuri S
Hum Vaccin Immunother
. 2018 Oct;
15(3):643-644.
PMID: 30352002
Since 2017, 10 vaccines are compulsory for newborns in Italy and unvaccinated children are not admitted to kindergartens. Recently the Italian Government announced the perspective of reforming the law about...
9.
Stucci S, Palmirotta R, Passarelli A, Silvestris E, Argentiero A, Lanotte L, et al.
Oncol Lett
. 2017 Nov;
14(5):5671-5680.
PMID: 29113194
Immunotherapy is one of the most recent systemic treatments to emerge for use in oncology, and is based on the blocking of inhibitory immune checkpoints to potentiate the immune response...
10.
Palmirotta R, Acquafredda S, Argentiero A, Carella C, Lanotte L, Pappagallo N, et al.
Recenti Prog Med
. 2016 Dec;
107(12):652-672.
PMID: 27997009
Diagnostic and therapeutic approaches to non small cell lung cancer (NSCLC), especially adenocarcinoma, have recently undergone dramatic evolution according to the tremendous amount of molecular data collected on this cancer....